Skip to main content
. 2019 May 14;3(9):1553–1562. doi: 10.1182/bloodadvances.2018030007

Table 3.

Investigator-assessed responses in treated patients (N = 33)

Best response n (%)
CR (bone marrow confirmed) 1 (3.0)
PR 19 (57.6)
PRL 5 (15.2)
Stable disease 6 (18.2)
ORR (≥ PR) 20 (60.6)
 95% CI* 42.1-77.1
ORR (≥ PRL) 25 (75.8)
 95% CI* 57.7-88.9
*

95% exact binomial confidence interval (CI).